|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0205210,
umls-concept:C0205307,
umls-concept:C0205464,
umls-concept:C0221099,
umls-concept:C0232741,
umls-concept:C0547040,
umls-concept:C1176289,
umls-concept:C1516213,
umls-concept:C1517132,
umls-concept:C1881878,
umls-concept:C2603343
|
|
pubmed:issue |
28
|
|
pubmed:dateCreated |
2006-9-29
|
|
pubmed:abstractText |
This study explored the feasibility of treating patients with impaired hepatic function with tipifarnib. The safety profile, pharmacokinetics, and relationship between the pharmacokinetics and toxicities were evaluated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4558-64
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17008695-Adult,
pubmed-meshheading:17008695-Aged,
pubmed-meshheading:17008695-Area Under Curve,
pubmed-meshheading:17008695-Farnesyltranstransferase,
pubmed-meshheading:17008695-Female,
pubmed-meshheading:17008695-Humans,
pubmed-meshheading:17008695-Liver,
pubmed-meshheading:17008695-Male,
pubmed-meshheading:17008695-Middle Aged,
pubmed-meshheading:17008695-Models, Statistical,
pubmed-meshheading:17008695-Neoplasms,
pubmed-meshheading:17008695-Neutrophils,
pubmed-meshheading:17008695-Quinolones,
pubmed-meshheading:17008695-Time Factors
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
|
|
pubmed:affiliation |
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. wan.les@quicknet.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
